Kopran Limited (524280) Fair Value & Analysis

Other · IN · Market cap ₹5.1B

Below-average quality, and screening another 38% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹161.32). The favourable scenario is already priced in.
• Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (₹87.32 to ₹161.32) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.

How to read this chart

60‑month range ₹93.16 – ₹338.05 · fair‑value band ₹87.32 – ₹161.32 · the ₹199.65 price screens above the ₹124.09 fair value. Dashed = 300-day average. As of Aug 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Kopran Limited (524280) currently trades at ₹199.65, while our model-based Fair Value estimate is ₹124.09, implying the stock looks roughly 37.9% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Kopran Limited generated revenue of ₹4.3B at a net margin of 9.8%. Revenue grew 35.6% year over year. It earns a return on equity of 21.1%. The stock trades on a trailing P/E of 12.9 (as of Aug 18, 2026). Fundamentals as of Aug 18, 2026

Our scenario range runs from ₹87.32 (bear case) to ₹161.32 (bull case); at ₹199.65, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 90% above its 52-week low. For context, the median of 10 Other peers we cover trades at -24% fair-value upside, at -38%, 524280 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (₹151.52) versus Dividend Discount (₹50.57). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally.

Full company description

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage forms, including tablets, capsules, dry powder, suspension, and injectable in various therapeutic areas comprising cardiovascular, gastrointestinal, pain management, oncology, anti-allergic, central nervous system, erectile dysfunction, and others, as well as antibiotics, anti-diabetic, respiratory, anthelmentics, antiprotozoals, and antipeptic ulcer and gut. It also provides active pharmaceutical ingredients in the categories of anti-hypertensive, macrolide, neuromodulator, sterile cephalosporins, carbapenems, anti-acne, anti-ulcerant, anti-depressent, anti-infective, urological, and anti-thrombotic. The company was incorporated in 1958 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Kopran Limited reported revenue of ₹6.3B in FY2025 versus ₹4.9B in FY2021, a compound +6.4%/yr. Reported net income was ₹386M in FY2025, compounding −11.1%/yr from FY2021.

524280 screens 38% overvalued. Compare with Federal Home Loan Mortgage Corporation →

Peer Group

Other · 393 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Other median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).

Explore undervalued stocks

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.